Windlas Biotech IPO - Direct Play On CMO Offers Alternative Opportunity For Investors: Prabhudas Lilladher
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Prabhudas Lilladher's IPO Report
Windlas Biotech is amongst top five players in contract development and manufacturing organisation segment with long list of large clientele from India formulations market.
A two-decade old company with experience in manufacturing (solid/ liquid) multiple dosage offers a comprehensive range of CDMO services in India.
Over time Windlas Biotech evolved as key CDMO players on the back of its:
presence in chronic products,
knowledge in research and development of process engineering,
wide customer base,
focus on trade generics and over-the-counter brands in India,
entry into injectable segment and
strong financial performance with experienced management.
It owns four plants at Dehradun with an aggregate installed capacity of 7 billion tablets/capsules, 55 million pouch/sachet and 61 million liquid bottles as on March 2021.
Click on the attachment to read the full IPO report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.